AMYRIS

Company Overview

Founded in 2003 as a spinout from the University of California, Berkeley, Amyris Inc. is developing and commercializing a synthetic biology platform for producing specialty chemicals. The company developed its Hyper-integration for rapid yeast strain engineering (Hi-Ryse) platform, which allows it to design, engineer, optimize, and scale up synthetic biology-developed organisms for industrial fermentation. Hi-Ryse uses site-specific genome engineering and high-throughput multiplexing for screening. This greatly reduces the development cycle for moving a molecule from conception to commercial production. The company has manufactured 13 unique ingredients, which are already available in the market for commercial use, along with 18 ingredients that are under development. The world leader in fragrance and beauty, Givaudan, Inc., announced that it has successfully acquired a significant portfolio of cosmetic ingredients from Amyris in February 2023.

Amyris markets synthetic biology-produced products in the skincare (No Compromise Beauty), fragrance, sweeteners (PureCane), and cosmetic industries. Amyris Inc. has more than 300 customer bases for its ingredients, which are used in approximately 20,000 products from the world’s top brands.

Company's Business Segments

• Products : The company generates revenue from products such as Sclareol, Hemisqualane, Santalols, Manool, Bisabolol, Biofene, Artemisinin, Biosilica, Others